LONDON (Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S. biotechnology company dropped a "poison pill" shareholder rights plan imposed to block the deal.
… Frangold : Just last month GlaxoSmithKline (NYSE: GSK ) was in the news for a move ..... the last as to the news of GlaxoSmithKline reiterating its $13 per ..... offer, which, according to GlaxoSmithKline , stands for a "full and …
… foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS, GlaxoSmithKline GSK , Roche, and Sanofi-Aventis. That said, we'd note that most of the firms included here are large multinational …
… by high-quality global firms such as Vodafone ( VOD ), British American Tobacco ( BTI ), HSBC ( HBC ), and GlaxoSmithKline ( GSK ). In fact, large-cap U.K. equities (in pound sterling) are actually less volatile than large-cap U …
May 21 (Reuters) - Auxilium Pharmaceuticals Inc and the U.S. unit of drugmaker GlaxoSmithKline said they will jointly sell Auxilium's testosterone gel, Testim, in the United States.
… ConocoPhillips ( COP ); Gannett Co ( GCI ); Dollar General Corporation ( DG ); General Electric Corp ( GE ); GlaxoSmithKline ( GSK ); Ingersoll-Rand ( IR ); M&T Bank Corp ( MTB ); Mastercard ( MA ); Moody's Corp ( MCO ); Procter …
LONDON, May 18 (Reuters) - An experimental cancer drug developed by Britain's GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday.
… Rocco Verducci : No sooner than the GlaxoSmithKline ( GSK ) $2.6 billion offer was announced ..... looking for an alternate suitor. GSK attempted to initiate a well-choreographed ..... reciprocal Kabuki-style movement toward GSK , but rather a highly dramatized …
… pipeline, and Mylan now joins Teva and Sandoz in attempting to make dry powder inhaler products to compete with GlaxoSmithKline 's GSK difficult-to-manufacture Advair Diskus. However, we currently place a low probability of approval on Mylan …
… stockholder rights plan, with a term of one year. Also says its board of directors unanimously determines GlaxoSmithKline 's ( GSK ) unsolicited tender offer is inadequate and not in the best interests of stockholders. Post your comment!